UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 28, 2014

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At November 3, 2014, 6,300,657,237 shares of the issuer s voting common stock were outstanding.

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended September 28, 2014 and September 29, 2013

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 28, 2014 and September 29, 2013

Condensed Consolidated Balance Sheets as of September 28, 2014 and December 31, 2013

Condensed Consolidated Statements of Cash Flows for the nine months ended September 28, 2014 and September 29, 2013

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

43

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

44

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

95

Item 4.

Controls and Procedures

95

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

96

Item 1A.

Risk Factors

96

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

97

Item 3.

Defaults Upon Senior Securities

97

Item 4.

Mine Safety Disclosures

97

Item 5.

Other Information

97

Item 6.

Exhibits

98

Signature

99

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

September 28,

2014

September 29,

2013

September 28,

2014

September 29,

2013

Revenues

12,361

12,643

36,487

38,026

Costs and expenses:

Cost of sales(a)

2,368

2,287

6,875

6,792

Selling, informational and administrative expenses(a)

3,556

3,395

10,116

10,203

Research and development expenses(a)

1,802

1,627

5,184

4,867

Amortization of intangible assets

972

1,117

3,090

3,476

Restructuring charges and certain acquisition-related costs

(19

233

120

547

Other (income)/deductions net

94

411

665

(514

Income from continuing operations before provision for taxes on income

3,587

3,573

10,437

12,655

Provision for taxes on income

911

985

2,575

3,876

Income from continuing operations

2,676

2,588

7,862

8,779

Discontinued operations:

Income from discontinued operations net of tax

(3

36

326

Gain on disposal of discontinued operations net of tax

(25

70

10,393

Discontinued operations net of tax

(3

11

70

10,719

Net income before allocation to noncontrolling interests

2,672

2,599

7,932

19,498

Less: Net income attributable to noncontrolling interests

25

63

Net income attributable to Pfizer Inc.

2,666

2,590

7,907

19,435

Earnings per common share basic:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.42

0.39

1.23

1.26

Discontinued operations net of tax

0.01

1.54

Net income attributable to Pfizer Inc. common shareholders

0.42

0.39

1.24

2.80

Earnings per common share diluted:

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.42

0.39

1.22

1.25

Discontinued operations net of tax

0.01

1.52

Net income attributable to Pfizer Inc. common shareholders

0.42

0.39

1.23

2.77

Weighted-average shares basic

6,330

6,581

6,363

6,938

Weighted-average shares diluted

6,403

6,656

6,441

7,016

Cash dividends paid per common share

0.26

0.24

0.78

0.72

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 28,

2014

September 29,

2013

September 28,

2014

September 29,

2013

Net income before allocation to noncontrolling interests

2,672

2,599

7,932

19,498

Foreign currency translation adjustments

(431

(21

(273

(1,068

Reclassification adjustments(a)

(62

171

(430

(21

(334

(897

Unrealized holding gains/(losses) on derivative financial instruments

(172

10

(229

143

Reclassification adjustments for realized (gains)/losses(b)

441

(339

527

(37

269

(329

298

106

Unrealized holding gains/(losses) on available-for-sale securities

(200

325

(107

137

Reclassification adjustments for realized (gains)/losses(b)

15

10

(163

(74

(185

335

(270

63

Benefit plans: actuarial gains/(losses), net

18

(13

13

34

Reclassification adjustments related to amortization(c)

48

137

146

438

Reclassification adjustments related to settlements, net(c)

19

54

58

147

Other

42

(28

16

112

127

150

233

731

Benefit plans: prior service credits and other

Reclassification adjustments related to amortization(c)

(19

(16

(55

(45

Reclassification adjustments related to curtailments, net(c)

12

(9

Other

(1

(4

(18

(14

(44

(55

Other comprehensive income/(loss), before tax

(238

121

(118

(52

Tax provision on other comprehensive income/(loss)(d)

83

80

71

443

Other comprehensive income/(loss) before allocation to noncontrolling interests

(320

41

(189

(495

Comprehensive income before allocation to noncontrolling interests

2,352

2,640

7,743

19,003

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(32

32

(2

Comprehensive income attributable to Pfizer Inc.

2,351

2,672

7,711

19,005

(a)

Reclassified into Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income.

(b)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(c)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(d)

See Note 5C. Tax Matters: Tax Provision on Other Comprehensive Income/(Loss).

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

September 28,

2014

December 31,

2013

(Unaudited)

Assets

Cash and cash equivalents

2,437

2,183

Short-term investments

31,009

30,225

Accounts receivable, less allowance for doubtful accounts: 2014 $388; 2013 $478

9,955

9,357

Inventories

6,355

6,166

Current deferred tax assets and other current tax assets

4,687

4,624

Other current assets

2,545

3,689

Total current assets

56,987

56,244

Long-term investments

18,451

16,406

Property, plant and equipment, less accumulated depreciation

12,032

12,397

Goodwill

42,724

42,519

Identifiable intangible assets, less accumulated amortization

36,374

39,385

Noncurrent deferred tax assets and other noncurrent tax assets

1,373

1,554

Other noncurrent assets

3,421

3,596

Total assets

171,362

172,101

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

5,389

6,027

Accounts payable

2,973

3,234

Dividends payable

1,663

Income taxes payable

892

678

Accrued compensation and related items

1,841

1,792

Other current liabilities

8,824

9,972

Total current liabilities

19,920

23,366

Long-term debt

31,666

30,462

Pension benefit obligations, net

4,364

4,635

Postretirement benefit obligations, net

2,591

2,668

Noncurrent deferred tax liabilities

26,320

25,590

Other taxes payable

3,930

3,993

Other noncurrent liabilities

4,266

4,767

Total liabilities

93,057

95,481

Commitments and Contingencies

Preferred stock

30

33

Common stock

455

453

Additional paid-in capital

78,498

77,283

Treasury stock

(71,820

(67,923

Retained earnings

74,292

69,732

Accumulated other comprehensive loss

(3,467

(3,271

Total Pfizer Inc. shareholders equity

77,988

76,307

Equity attributable to noncontrolling interests

317

313

Total equity

78,305

76,620

Total liabilities and equity

171,362

172,101

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS OF DOLLARS)

September 28,

2014

September 29,

2013

Operating Activities

Net income before allocation to noncontrolling interests

7,932

19,498

Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:

Depreciation and amortization

4,206

4,921

Asset write-offs and impairments

414

908

Gain associated with the transfer of certain product rights to an equity-method investment

(459

Gain on disposal of discontinued operations

(65

(10,501

Deferred taxes from continuing operations

766

1,667

Deferred taxes from discontinued operations

(23

Share-based compensation expense

424

418

Benefit plan contributions (in excess of)/less than expense

(208

242

Other adjustments, net

(464

38

Other changes in assets and liabilities, net of acquisitions and divestitures

(1,519

(4,749

Net cash provided by operating activities

11,485

11,960

Investing Activities

Purchases of property, plant and equipment

(845

(789

Purchases of short-term investments

(36,294

(33,927

Proceeds from redemptions and sales of short-term investments

32,883

29,008

Net (purchases of)/proceeds from redemptions/sales of investments with original maturities of 90 days or less

4,945

(2,177

Purchases of long-term investments

(9,254

(8,746

Proceeds from redemptions and sales of long-term investments

4,637

5,943

Acquisitions of businesses, net of cash acquired

(195

(15

Acquisitions of intangible assets

(342

(177

Other investing activities, net

325

194

Net cash used in investing activities

(4,140

(10,686

Financing Activities

Proceeds from short-term borrowings

3,723

Principal payments on short-term borrowings

(3

(3,776

Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less

(2,758

1,831

Proceeds from issuance of long-term debt(a)

4,491

6,618

Principal payments on long-term debt

(786

(2,396

Purchases of common stock

(3,801

(11,643

Cash dividends paid

(4,970

(5,026

Proceeds from exercise of stock options

704

1,370

Other financing activities, net

56

68

Net cash used in financing activities

(7,060

(9,231

Effect of exchange-rate changes on cash and cash equivalents

(30

(72

Net increase/(decrease) in cash and cash equivalents

255

(8,029

Cash and cash equivalents, beginning

2,183

10,081

Cash and cash equivalents, end

2,437

2,052

Supplemental Cash Flow Information

Non-cash transactions:

Sale of subsidiary common stock (Zoetis) for Pfizer common stock(b)

11,408

Exchange of subsidiary common stock (Zoetis) for the retirement of Pfizer commercial paper issued in 2013(b)

2,479

Exchange of subsidiary senior notes (Zoetis) for the retirement of Pfizer commercial paper issued in 2012(b)

992

Transfer of certain product rights to an equity-method investment (Hisun Pfizer)(c)

1,233

Cash paid during the period for:

Income taxes

1,484

1,799

Interest

1,329

1,512

(a)

In 2013, includes $2.6 billion from the issuance of senior notes by Zoetis (our former Animal Health subsidiary), net of the $1.0 billion non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.

(b)

See Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.

(c)

See Note 2D. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Equity-Method Investments.

Amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 24, 2014 and August 25, 2013.

In the condensed consolidated statements of comprehensive income, we have revised the presentation of other comprehensive income/(loss) shown in prior periods for derivative financial instruments and available-for-sale securities, as certain items had been reported net. In the condensed consolidated statements of cash flows, we have revised the classification of certain items shown in prior periods, none of which had a significant impact.

On June 24, 2013, we completed the full disposition of our Animal Health business, Zoetis Inc. (Zoetis), and recognized a gain of approximately $10.4 billion, net of tax, in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013. The operating results of this business through June 24, 2013, the date of disposal, are reported as Discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013. For additional information, see Note 2B. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments: Divestiture.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2013 Annual Report on Form 10-K.

Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.

B. Adoption of New Accounting Standards

We adopted the following new accounting and disclosure standards as of January 1, 2014 and there were no impacts to our condensed consolidated financial statements:

A new standard that clarified the accounting for cumulative translation adjustment (CTA) upon derecognition of a group of assets that is a business or an equity-method investment within a foreign entity.

A new standard regarding the measurement of obligations resulting from joint and several liability arrangements that may include debt agreements, other contractual obligations and settled litigation or judicial rulings.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2. Acquisition, Divestiture, Licensing Arrangements and Equity-Method Investments

A. Acquisition

InnoPharma, Inc. (InnoPharma)

On September 24, 2014, we completed our acquisition of InnoPharma, a privately-held pharmaceutical development company, for an upfront cash payment of $225 million and contingent consideration with an estimated acquisition-date fair value of approximately $67 million. The contingent consideration consists of up to $135 million in additional milestone payments based on application filing with and acceptance by the U.S. Food and Drug Administration (FDA), or approval of marketing applications related to certain pipeline products by the FDA. We believe this acquisition represents a potential innovative growth opportunity for our sterile injectables portfolio in areas such as oncology and central nervous disorders. In connection with this acquisition, we recorded $247 million in Identifiable intangible assets, consisting of $212 million in In-process research and development (IPR&D) and $35 million in Developed technology rights; $81 million in net deferred tax liabilities; and $125 million in Goodwill. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not been finalized.

B. Divestiture

Animal Health Business (Zoetis)

On June 24, 2013, we completed the full disposition of Zoetis. The full disposition was completed through a series of steps, including, in the first quarter of 2013, the formation of Zoetis and an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and, in the second quarter of 2013, an exchange offer for the remaining 80.2% interest.

With respect to the formation and disposition of Zoetis, in the first nine months of 2013:

Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.

Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' option to purchase additional shares, which was exercised in full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital.

Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis for Pfizer common stock and recognized a gain on sale of approximately $10.4 billion net of income taxes resulting from certain legal entity reorganizations, which was recorded in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013.

The operating results of the Animal Health business through June 24, 2013, the date of disposal, are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Total Discontinued Operations

The following table provides the components of Discontinued operations net of tax, virtually all of which relates to Zoetis:

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 28,

2014

September 29,

2013

September 28,

2014

September 29,

2013

Revenues

2,201

Pre-tax income from discontinued operations(b)

(2

32

421

Provision for taxes on income(a)

(4

95

Income from discontinued operations net of tax

(3

36

326

Pre-tax gain on disposal of discontinued operations(b)

(38

65

10,501

Provision for taxes on income(b), (c)

(13

(4

108

Gain on disposal of discontinued operations net of tax(b)

(25

70

10,393

Discontinued operations net of tax

(3

11

70

10,719

(a)

Includes a deferred tax expense of $2 million and a deferred tax benefit of $4 million for the three months ended September 28, 2014 and September 29, 2013, respectively, and a deferred tax benefit of $23 million for the nine months ended September 29, 2013. Deferred taxes for the first nine months of 2014 were nil.

(b)

For the three months and nine months ended September 28, 2014 and for the three months ended September 29, 2013, represents post-close adjustments.

(c)

For the nine months ended September 29, 2013, reflects income taxes resulting from certain legal entity reorganizations.

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the nine months ended September 29, 2013, except that financing activities include the cash proceeds from the issuance of senior notes by Zoetis.

C. Licensing Arrangements

Cellectis SA (Cellectis)

On June 18, 2014, we entered into a global strategic arrangement with Cellectis to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select cellular surface antigen targets. In August 2014, we made an upfront payment of $80 million to Cellectis, which was recorded in Research and development expenses, and we will also fund research and development costs associated with the 15 Pfizer-selected targets and the four Cellectis-selected targets within the arrangement. Cellectis is eligible to receive development, regulatory and commercial milestone payments of up to $185 million per product that resulted from the Pfizer-selected targets. Cellectis is also eligible to receive tiered royalties on net sales of any products that are commercialized by Pfizer. In addition, in August 2014, we acquired approximately 10% of the Cellectis capital through the purchase of newly issued shares, for a total investment of approximately $35 million.

Nexium Over-the-Counter Rights

In connection with our August 2012 agreement with AstraZeneca PLC (AstraZeneca) for the exclusive, global, over-the-counter rights for Nexium, a leading prescription drug currently approved to treat the symptoms of gastroesophageal reflux disease, (i) on May 27, 2014, we launched Nexium 24HR in the U.S., and on July 11, 2014, we paid AstraZeneca a related $200 million product launch milestone payment and (ii) on August 1, 2014, we launched Nexium Control in Europe, and on September 15, 2014, we paid AstraZeneca a related $50 million product launch milestone payment. The milestone payments for this Consumer Healthcare asset acquisition have been recorded in Identifiable intangible assets, less accumulated amortization in the condensed consolidated balance sheet and will be amortized over their estimated useful lives. AstraZeneca is eligible to receive future milestone payments of up to $300 million, based on product launches outside the U.S. and level of worldwide sales and is eligible to receive royalty payments, based on worldwide sales.

D. Equity-Method Investments

Investment in Laborat rio Teuto Brasileiro (Teuto)

We have an option to acquire the remaining 60% of Teuto, a 40%-owned generics company in Brazil, beginning in 2014, and Teuto s majority shareholders have an option to sell their 60% stake to us beginning in 2015.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In the third quarter and first nine months of 2013, we recorded an estimated loss of approximately $223 million related to the net call/put option and an impairment loss of $32 million related to our equity-method investment, both of which were recorded in Other (income)/deductions net.

In the third quarter and first nine months of 2014, we recorded income of approximately $90 million resulting from a decline in the estimated loss from the aforementioned option, which was recorded in Other (income)/deductions net.

Investment in ViiV Healthcare Limited (ViiV)

Our minority ownership interest in ViiV, a company formed by Pfizer and GlaxoSmithKline plc (GSK) to focus solely on research, development and commercialization of human immunodeficiency virus (HIV) medicines, was impacted by the following events:

The January 21, 2014 European Commission approval of Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV. This approval triggered a reduction in our equity interest in ViiV from 12.6% to 11.7%, effective April 1, 2014. As a result, in the first nine months of 2014, we recognized a loss of approximately $30 million in Other (income)/deductions net; and

The August 12, 2013 FDA approval of Tivicay (dolutegravir). This approval triggered a reduction in our interest in ViiV from 13.5% to 12.6%, effective October 1, 2013. As a result, in the third quarter and first nine months of 2013, we recognized a loss of approximately $31 million in Other (income)/deductions net.

Investment in Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer)

In connection with the September 6, 2012 formation of Hisun Pfizer in conjunction with Zhejiang Hisun Pharmaceuticals Co., Ltd. (Hisun), a leading pharmaceutical company in China, in the first quarter of 2013, we and Hisun contributed certain assets to Hisun Pfizer. Hisun Pfizer is 49% owned by Pfizer and 51% owned by Hisun. Our contributions constituted a business, as defined by U.S. GAAP, and in the first nine months of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income) deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our former Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we had an indirect retained interest in the contributed assets. As such, 49% of the gain, or $225 million, represented the portion of the gain associated with that indirect retained interest.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization and optimization actions, workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development (R&D), as well as groups such as information technology, shared services and corporate operations.

At the end of 2013, we had substantially completed many of the initiatives launched in prior periods. In early 2014, we announced that we would be incurring costs in 2014-2016 related to new programs: our new global commercial structure reorganization and additional cost-reduction/productivity initiatives.

In 2014, we have the following initiatives underway:

Manufacturing plant network rationalization and optimization, where execution timelines are necessarily long. Our plant network strategy is expected to result in the exit of eight sites over the next several years (down from 10 sites, previously, as two sites have been sold). In connection with these activities, during 2014-2016, we expect to incur costs of approximately $400 million associated with prior acquisition activity and costs of approximately $1.4 billion associated with new non-acquisition-related cost-reduction initiatives.

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

New global commercial structure reorganization, which primarily includes the streamlining of certain functions, the realignment of regional locations and colleagues to support the businesses, as well as implementing the necessary system changes to support future reporting requirements. In connection with this reorganization, during 2014-2016, we expect to incur costs of approximately $350 million.

Other new cost-reduction/productivity initiatives, primarily related to commercial property rationalization and consolidation. In connection with these cost-reduction activities, during 2014-2016, we expect to incur costs of approximately $850 million.

The costs expected to be incurred during 2014-2016, of approximately $3.0 billion in total, include restructuring charges, integration costs, implementation costs and additional depreciation asset restructuring. Of this amount, we expect that about a quarter of the charges will be non-cash.

Current-Period Key Activities

In the first nine months of 2014, we incurred approximately $531 million in cost-reduction and acquisition-related costs (excluding transaction costs) in connection with the aforementioned programs, primarily associated with our manufacturing and sales operations.

The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 28,

2014

September 29,

2013

September 28,

2014

September 29,

2013

Restructuring charges(a):

Employee terminations

(51

174

(4

289

Asset impairments

28

115

Exit costs

21

44

36

Total restructuring charges

(38

195

68

440

Integration costs(b)

19

38

53

107

Restructuring charges and certain acquisition-related costs

(19

233

120

547

Additional depreciation asset restructuring recorded in our condensed consolidated statements of income as follows(c):

Cost of sales

52

43

199